Cytotoxic drugs are used as immunosuppressive treatment for complications of juvenile chronic arthritis that do not respond to other forms of treatment. Amyloidosis is usually life threatening, but if the disease can be controlled by chlorambucil, life expectancy is improved.' Other complications such as uveitis, which are associated with a high morbidity but low mortality, may also improve with chlorambucil.2 Unfortunately these children are at risk of developing drug induced malignancies, 3 4 which are almost exclusively acute leukaemias, and which may develop many years after stopping cytotoxic drugs.5
The concern that has been expressed about the use of chlorambucil for childhood nephrosis6 applies equally to its use for juvenile chronic arthritis. It in months (P<0-05). Similarly, the total past dose is also important in determining sister chromatid exchange frequencies (P<0-05).
The sister chromatid exchanges of two patients have been assessed on two occasions separated by a year or more. In each case, the sister chromatid exchanges increased as the treatment period lengthened: for one patient the mean frequency was 9-5 after 38 months of treatment increasing to 12-5 some 12 months later, and for the other patient the mean frequency was 13-8 after 88 months of treatment increasing to 15-2 some 14 months later. The daily doses of chlorambucil did not change between the two assessments.
Nine patients had received chlorambucil in the past but were not receiving this drug at the time of the study (Tables 1 and 3, Fig. 2 ). Their sister chromatid exchanges are higher than those of the control group (P<0-01), and although abnormal frequencies were present in one patient five months after stopping treatment, they were normal in those who had been off treatment for 36 months or more.
Discussion
These observations show that sister chromatid exchange analysis is a very sensitive measure of chromosome damage induced by chlorambucil used as immunosuppressive treatment for children with juvenile chronic arthritis. The extent of chromosome damage is closely related to the present daily dose, and although the analysis of the results is complicated by the drug regimens that are used for these patients, it is likely that the extent of chromosome damage is also determined by the total dose received or the duration of treatment. The sister chromatid exchanges of two patients who were studied twice increased with the duration of treatment. These observations suggest that chromosome damage induced by chlorambucil is cumulative, and that in some cells, damage is long lived and possibly permanent. They are consistent with our previously reported observations on the genotoxic effects of chlorambucil in adult patients,8 and also with clinical studies on chlorambucil induced malignancies. The risk of developing leukaemia after treatment with this drug is related to the duration of treatment and total past intake in adult patients with rheumatic diseases12 and others with polycythaemica vera.13 Some patients develop chlorambucil induced leukaemias many months or years after stopping the drug,5 suggesting that the damage to cells that undergo malignant transformation is long lived and possibly permanent. The in vivo positive dose-response effect of chlorambucil that has been observed in our patients has also been shown in vitro. 14 In general, the mean sister chromatid exchange frequencies of patients who have stopped chlorambucil are lower than those who are continuing treatment. It seems that frequencies can remain high for at least five months, but that they have returned to normal by 36 months. This longevity has not been previously reported; most 
